BTK and B-cell chronic lymphocytic leukemia: The combination of selinexor and ibrutinib (NCT02303392) was tolerable and associated with clinical responses in heavily pre-treated CLL patients, including those with BTK mutations and Richter’s transformation [10], however further strategies are required however to improve the depth of response.